Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/20/2026, 12:00:00 AM
An appeals panel in the U.K. ruled on March 20, 2026, that the National Institute for Health and Care Excellence (NICE) must reconsider its previous negative recommendation against the reimbursement of the Alzheimer's drug Leqembi (lecanemab). This event is estimated to have a medium impact due to the potential for expanded market access.
Korean Translation
2026년 3월 20일, 영국 항소 패널은 국립보건임상연구원(NICE)이 알츠하이머 치료제 레켐비(레카네맙)에 대한 이전의 부정적인 급여 권고를 재고해야 한다고 판결함. 시장 접근성 확대 가능성으로 중간 수준의 영향이 예상됨.
Related Recent Events
Novo Nordisk A/S (NVO) · Other
Announced on Feb 24, 2026, that it will lower the U.S. list prices of key drugs Wegovy and Ozempic by approximately 50% and 35% respectively, effective January 1, 2027, to improve patient access.
1/1/2027, 12:00:00 AM
Novartis AG (NVS) · Other
Results from the Phase III Lp(a)HORIZON study of cardiovascular candidate pelacarsen are scheduled for 2026-06-30; this key clinical readout is estimated to have a >5% price impact expected.
6/30/2026, 12:00:00 AM
RELX PLC (RELX) · Other
Ex-dividend date for the 48.0 pence per share final dividend for fiscal year 2025 on May 7, 2026; dividend-related price adjustments are typically low, scheduled
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Leidos is scheduled to release Q1 2026 financial results on May 5, 2026, with analysts forecasting EPS of $2.91-$2.94 expected.
5/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer's Q1 2026 earnings release is scheduled for May 5, 2026, scheduled.
5/5/2026, 12:00:00 AM